Literature DB >> 26190457

Comparison of volume-reductive therapies for massive polycystic liver disease in autosomal dominant polycystic kidney disease.

Jaeseok Yang1, Hyunjin Ryu2, Miyeun Han2, Hyunsuk Kim2, Young-Hwan Hwang3, Jin Wook Chung4, Nam-Joon Yi5, Kwang-Woong Lee5, Kyung-Suk Suh5, Curie Ahn1,2.   

Abstract

AIM: Polycystic liver disease (PLD) in autosomal dominant polycystic kidney disease (ADPKD) patients can induce massive hepatomegaly-related symptoms. Volume-reductive therapies for symptomatic PLD include transcatheter arterial embolization (TAE), liver resection and liver transplantation; however, consensus has not been reached regarding treatment selection. We compared three volume-reductive therapies for a better understanding of PLD treatment strategies.
METHODS: We retrospectively analyzed 28 ADPKD patients who underwent TAE, liver resection or liver transplantation for PLD at a single center, and compared their outcomes.
RESULTS: Of 18 TAE patients, five required repeat TAE, and five required rescue liver transplantation or liver resection because of refractory symptoms or hepatic failure. The treatment failure rate for TAE was high (69.6%). Nine underwent liver resection, and the degree of volume reduction in the liver resection group was greater than that in the TAE group (52.4% vs 7.6%, P < 0.001). One liver resection patient required rescue liver transplantation because of hepatic failure. Seven patients underwent liver transplantations. All liver transplant patients had successfully controlled symptoms or hepatic failure, and had good graft function. Three patients in the TAE group died of infections or hepatic failure, whereas no mortality occurred after surgical therapy.
CONCLUSION: Liver resection is a good first-line therapy in patients that have severe symptoms, cyst involvement in several segments with some spared segments and preserved liver function. Liver transplantation is a preferred first-line therapy in patients with poor liver function or whole-liver involvement. Liver transplantation is also a good rescue therapy following TAE or liver resection.
© 2015 The Japan Society of Hepatology.

Entities:  

Keywords:  autosomal dominant polycystic kidney disease; liver resection; liver transplantation; polycystic liver disease; transcatheter arterial embolization

Year:  2015        PMID: 26190457     DOI: 10.1111/hepr.12560

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  8 in total

Review 1.  Polycystic kidney disease.

Authors:  Carsten Bergmann; Lisa M Guay-Woodford; Peter C Harris; Shigeo Horie; Dorien J M Peters; Vicente E Torres
Journal:  Nat Rev Dis Primers       Date:  2018-12-06       Impact factor: 52.329

Review 2.  Polycystic Liver Disease: Pathophysiology, Diagnosis and Treatment.

Authors:  Luiz Fernando Norcia; Erika Mayumi Watanabe; Pedro Tadao Hamamoto Filho; Claudia Nishida Hasimoto; Leonardo Pelafsky; Walmar Kerche de Oliveira; Ligia Yukie Sassaki
Journal:  Hepat Med       Date:  2022-09-29

Review 3.  Genetics, pathobiology and therapeutic opportunities of polycystic liver disease.

Authors:  Paula Olaizola; Pedro M Rodrigues; Francisco J Caballero-Camino; Laura Izquierdo-Sanchez; Patricia Aspichueta; Luis Bujanda; Nicholas F Larusso; Joost P H Drenth; Maria J Perugorria; Jesus M Banales
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-05-13       Impact factor: 73.082

4.  Total kidney and liver volume is a major risk factor for malnutrition in ambulatory patients with autosomal dominant polycystic kidney disease.

Authors:  Hyunjin Ryu; Hyosang Kim; Hayne Cho Park; Hyunsuk Kim; Eun Jin Cho; Kyu-Beck Lee; Wookyung Chung; Kook-Hwan Oh; Jeong Yeon Cho; Young-Hwan Hwang; Curie Ahn
Journal:  BMC Nephrol       Date:  2017-01-14       Impact factor: 2.388

5.  Transarterial Embolization for Treatment of Symptomatic Polycystic Liver Disease: More than 2-year Follow-up.

Authors:  Jin-Long Zhang; Kai Yuan; Mao-Qiang Wang; Jie-Yu Yan; Hai-Nan Xin; Yan Wang; Feng-Yong Liu; Yan-Hua Bai; Zhi-Jun Wang; Feng Duan; Jin-Xin Fu
Journal:  Chin Med J (Engl)       Date:  2017-08-20       Impact factor: 2.628

6.  Bioelectrical impedance analysis as a nutritional assessment tool in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Hyunjin Ryu; Hayne Cho Park; Hyunsuk Kim; Jongho Heo; Eunjung Kang; Young-Hwan Hwang; Jeong Yeon Cho; Kyu-Beck Lee; Yun Kyu Oh; Kook-Hwan Oh; Curie Ahn
Journal:  PLoS One       Date:  2019-04-04       Impact factor: 3.240

7.  Severe polycystic liver diseases: hepatectomy or waiting for liver transplantation?: Two case reports.

Authors:  Zeyu Zhang; Kuan Hu; Jiajin Yang; Yufan Zhou; Zhiming Wang; Yun Huang
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.889

8.  Evidence of nonsurgical treatment for polycystic liver disease.

Authors:  Jeong-Ju Yoo; Hye In Jo; Eun-Ae Jung; Jae Seung Lee; Sang Gyune Kim; Young Seok Kim; Beom Kyung Kim
Journal:  Ther Adv Chronic Dis       Date:  2022-07-21       Impact factor: 4.970

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.